ImmunoGen signs loan agreement with Pharmakon for up to $175m
2023-04-06
引进/卖出抗体药物偶联物临床1期
Preview
来源: Pharmaceutical Technology
The second tranche of $50m will be provided after reporting positive top-line data from the confirmatory MIRASOL trial and upon meeting a sales threshold for ELAHERE. Credit: PublicDomainPictures from Pixabay.
US-based biotechnology company ImmunoGen has signed a term loan financing facility worth up to $175m with the entities of Pharmakon Advisors.
ImmunoGen will use the proceeds from the agreement to support its growth trajectory and bolster its balance sheet.
The company will receive the loan facility in two tranches.
The first tranche of $75m will be available to the company once the agreement has been executed.
The second tranche of $50m will be provided after reporting positive top-line data from its confirmatory MIRASOL trial, and subject to a net sales threshold for ELAHERE (mirvetuximab soravtansine-gynx), which is indicated for treatment of patients with platinum-resistant ovarian cancer.
“Pharmakon is a well-respected partner to innovative biotechnology companies, and we look forward to utilising the non-dilutive capital from this agreement to advance the business and drive value for our shareholders as a commercial oncology company.”
ELAHERE is a first-in-class ADC that includes a folate receptor alpha-binding antibody, a cleavable linker and a tubulin inhibitortubulin inhibitor (maytansinoid payload DM4), which can kill the targeted cancer cells.
Upon mutual agreement by the parties, the second tranche may be increased to $100m. The loan facility will have a maturity period of five years.
Pharmakon managing member Martin Friedman said: “We are pleased to support ImmunoGen, and this investment illustrates our confidence in the company’s ability to successfully commercialise ELAHERE while progressing the development of its earlier-stage assets and delivering on its mission to offer more good days to patients.”
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
靶点
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。